Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rexall Sundown

This article was originally published in The Tan Sheet

Executive Summary

President Damon DeSantis assumes additional post of CEO with Chris Nast's appointment to vice chairman. DeSantis joined Rexall in 1983 and was named president in early 1998. Nast joined the company in 1995 as president and chief operating officer and assumed the role of CEO in 1997. Separately, the firm announces exclusive U.S. distribution rights to Italian firm Medestea International's Cellasene dietary supplement, which claims to "Help eliminate cellulite." The softgel product contains ginkgo biloba to help increase circulation and grape seed extract, an antioxidant. Launching in food, drug and mass market outlets nationwide in March, a 10-day supply retails for approximately $40. Rexall also has rights for Cellasene in several foreign markets

You may also be interested in...



People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

UsernamePublicRestriction

Register

PS089518

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel